Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey

To develop a benchmark measure of US physicians' level of knowledge and extent of use of pharmacogenomic testing, we conducted an anonymous, cross‐sectional, fax‐based, national survey. Of 397,832 physicians receiving the survey questionnaire, 10,303 (3%) completed and returned it; the responde...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2012-03, Vol.91 (3), p.450-458
Main Authors: Stanek, E J, Sanders, C L, Taber, K A Johansen, Khalid, M, Patel, A, Verbrugge, R R, Agatep, B C, Aubert, R E, Epstein, R S, Frueh, F W
Format: Article
Language:English
Subjects:
Adult
Aged
Attitude of Health Personnel
Cross-Sectional Studies - methods
Data Collection - methods
Female
Genetic Testing - methods
Genetic Variation
Health Knowledge, Attitudes, Practice
Humans
Logistic Models
Male
Middle Aged
Multivariate Analysis
Pharmacogenetics
Practice Patterns, Physicians
Surveys and Questionnaires
United States
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To develop a benchmark measure of US physicians' level of knowledge and extent of use of pharmacogenomic testing, we conducted an anonymous, cross‐sectional, fax‐based, national survey. Of 397,832 physicians receiving the survey questionnaire, 10,303 (3%) completed and returned it; the respondents were representative of the overall US physician population. The factors associated with the decision to test were evaluated using χ2 and multivariate logistic regression. Overall, 97.6% of responding physicians agreed that genetic variations may influence drug response, but only 10.3% felt adequately informed about pharmacogenomic testing. Only 12.9% of physicians had ordered a test in the previous 6 months, and 26.4% anticipated ordering a test in the next 6 months. Early and future adopters of testing were more likely to have received training in pharmacogenomics, but only 29.0% of physicians overall had received any education in the field. Our findings highlight the need for more effective physician education on the clinical value, availability, and interpretation of pharmacogenomic tests. Clinical Pharmacology & Therapeutics (2012); 91 3, 450–458. doi:10.1038/clpt.2011.306
ISSN:0009-9236
1532-6535
DOI:10.1038/clpt.2011.306